Investors
Company Overview
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid and oncological diagnostics and therapeutics. AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.
The company’s subsidiary, Sapphire Biotech, Inc., is conducting research to understand the potential of its lead drug candidate, SPX-1009, to block the spread of tumor metastasis. Additionally, Sapphire’s proprietary diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.
Investor Presentation
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009
SAN DIEGO, June 1, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has...
AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
SAN DIEGO – May 27, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today it has expanded its research division through...
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood NEW YORK – May 18, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting...
